ArticleScientific reports2026
Development of β-CD metal organic frameworks loaded with olaparib: a novel approach for the treatment of cervical cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the current study, a highly porous β-CD-metal organic frameworks (βCD-MOFs) was prepared and drug, olaparib (OP) was loaded successfully in order to enhance the efficacy of OP for the treatment of cervical cancer. The produced OP-loaded βCD-MOFs were assessed using TC-1 cell lines for drug encapsulation, FTIR, DSC, TGA, PXRD, in vitro release studies, SEM, and MTT assay. βCD-MOFs successfully encapsulated the OP with a high efficiency of 76.48%, due to structural advantages of βCD-MOFs. In-vitro release studies exhibited a sustained release pattern for 24 h. As compared to free-OP, we observed a significant reduction in cell viability and lowered inhibitory concentration IC50 (13.52 nM) in TC-1 cells treated with OP-loaded βCD-MOFs. Additionally, p53 and caspase 9 were elevated by the OP-loaded βCD-MOFs, suggesting an effective apoptosis that may hold promise for the therapy of cervical cancer. Overall, OP-loaded βCD-MOFs could be alternative to conventional formulation of OP in treating cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.